Evaluate MedTech World Preview 2017, Outlook to 2022

Report Highlights

  • Total value of medtech M&A deals rises by a massive 178% in H1 2017
  • In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022
  • Venture capital investment looks to be on track to at least match 2016’s total
  • Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%
Thumbnail
Thumbnail
Thumbnail

Download the latest edition of EvaluateMedTech World Preview 2017, Outlook to 2022 showing with Medtronic is the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn.

Our annual report highlights trends in medtech including: consensus sales forecasts of leading industry analysts by device area to 2022; the top 20 companies in 2022; R&D spend current and future; FDA approvals; M&A; venture financing; IPOs; and enterprise value.

This analysis is based on in-depth consensus forecast models for the top 300 global medtech companies available within the EvaluateMedTech service. 

Download Report

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.